CANCER IN CHILDREN

宾夕法尼亚大学儿科血液肿瘤学系 密歇根医学中心合作进行所有儿童开放性研究 癌症小组，目标是改善儿童的护理和生存 得了癌症该部门是密歇根大学癌症的成员 中心，一个N.C.I.综合癌症中心，该州两个综合癌症中心之一， 密歇根州，并有9名全职临床研究人员与教师 密歇根大学医学院的任命，以及 批准的儿科血液肿瘤学奖学金计划， 研究员每年接受三年的培训。此外，参与 CCG研究活动通过与五个国家的合作得到加强 位于密歇根州人口较多地区的附属机构 (two在底特律地区，一个在大急流城，一个在东兰辛， 一个在卡拉马祖）;附属机构的数量从一个增加到一个， 在上一次竞争性续约时，目前有五个。CCG患者 截至2011年12月31日， 1992年7月31日（CCG机构中的第十四名），总学习 同年的参赛人数为237人（在CCG机构中排名第六）; 99人 这些是一线治疗研究项目（CCG中第八 机构），132例为非治疗性研究（CCG中第三 机构）。此外，该网络积极跟踪795名患者， （在CCG机构中排名第十）。这些数字都要高得多 比去年竞争对手的申请，在后续的数量更多 是1988年的两倍多。密歇根大学是17所 CCG机构批准参与第一阶段研究，是一个 CCG批准的骨髓移植中心，后者批准新的，因为 最后一个竞争对手。共11个多学科 调查人员有任命科学，纪律，和研究 委员会和战略小组。未来，这些研究人员在 密歇根大学将继续为CCG治疗做出贡献， 流行病学和广泛的恶性疾病的生物学研究。 在I期临床试验领域， 试验和骨髓移植。最后，新的研究人员在 大学的儿科血液肿瘤学目前正在制作 对神经母细胞瘤和软组织分子生物学的贡献 这些研究可能会扩展到CCG的临床试验 为了评估临床相关性和预后重要性， 的调查结果。

The Division of Pediatric Hematology-Oncology at the University of Michigan Medical Center collaborates in all open studies of the Childrens Cancer Group, with the goal of improving the care and survival of children with cancer. The Division is a member of the University of Michigan Cancer Center, an N.C.I. Comprehensive Cancer Center, one of two in the State of Michigan, and has nine full-time clinical investigators with faculty appointments at the University of Michigan Medical School, as well as an approved fellowship program in pediatric hematology-oncology with two fellows in training for each of three years. In addition, participation in CCG research activities is enhanced through collaboration - with five affiliate institutions located in the more populous regions of Michigan (two in the Detroit area, one in Grand Rapids, one in East Lansing, and one in Kalamazoo); the number of affiliate institutions has grown from one at the time of the last competitive renewal to five currently. CCG patient registrations from the affiliate network numbered 176 for the year ending July 31, 1992 (fourteenth among CCG institutions), with total study entries equaling 237 for the same year (sixth among CCG institutions); 99 of these were first-line therapeutic study entries (eighth among CCG institutions), and 132 were non-therapeutic study entries (third among CCG institutions). Furthermore, the network actively follows 795 patients (tenth among CCG institutions). These numbers are all considerably higher than at last competitive application, with the number in follow-up more than double the number in 1988. The University of Michigan is one of 17 CCG institutions approved for participation in phase I studies and is a CCG-approved bone marrow transplant center, the latter approval new since the last competitive submission. A total of 11 multidisciplinary investigators have appointments to scientific, discipline, and study committees and to strategy groups. In the future, these investigators at the University of Michigan will continue to contribute to CCG therapeutic, epidemiology, and biology research for a wide range of malignant diseases. Additional contributions can be expected in the areas of phase I clinical trails and bone marrow transplantation. Finally, new investigators in Pediatric Hematology-Oncology at the University are currently making contributions to the molecular biology of neuroblastoma and soft tissue sarcoma; these studies will likely be expanded to clinical trials in CCG in order to evaluate the clinical relevance and the prognostic importance of the findings.